Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Novartis AG
Industry Sector: HealthTechnology
CEO: Vasant Narasimhan, MD
Number Of Employees: 75,883
Enterprise Value: $217,984,437,334
PE Ratio: 18.92
Exchange/Ticker 1: SIX:NOVN
Exchange/Ticker 2: NYSE:NVS
Latest Market Cap: $212,253,133,037
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Mar 20, 2025
Regulation
Amvuttra’s label expansion lifts Alnylam toward five-year goals
Non-GAAP profitability in sight as RNAi therapeutic adds cardiomyopathy indication alongside previous amyloidosis approval
BioCentury | Mar 19, 2025
Market Access
Patient death resurfaces safety concerns for Sarepta’s gene therapy
But it’s unclear that market access will be affected
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Mar 13, 2025
Product Development
Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation
How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity
BioCentury | Mar 13, 2025
Management Tracks
Scarlett steps down as CEO of Geron
Plus: Purespring names Haseeb Ahmad CEO, and updates from Cellevate and Moffitt Cancer Center
BioCentury | Mar 12, 2025
Product Development
Autoimmune CAR T companies compete for resources
Crowding in the autoimmune CAR T field brings recruitment challenges
BioCentury | Mar 7, 2025
Data Byte
MS market dynamics: Ocrevus still king as Kesimpta sales boom
Plus: Briumvi shows signs of growth, while sales of oral therapies remain mostly flat
Items per page:
1 - 10 of 8777